Email this article Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice
- Authors: Shapina M.V.1, Nanaeva B.A.1
-
Affiliations:
- Ryzhikh State Scientific Centre of Coloproctology
- Issue: Vol 92, No 2 (2020)
- Pages: 67-73
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/33909
- DOI: https://doi.org/10.26442/00403660.2020.02.000528
- ID: 33909
Cite item
Full Text
Abstract
Vedolizumab is currently the only selective biological drug for the treatment of inflammatory bowel diseases (IBD). Its effectiveness and safety has been shown in clinical trials. This article presents the experience of using vedolizumab in real clinical practice in patients with various forms of ulcerative colitis (UC) and Crohn’s disease (CD).
Materials and methods. 96 patients with IBD (62 with CD and 34 with UC) were prescribed therapy with vedolizumab at a dose of 300 mg intravenously at 0, 2, and 6 weeks, and further maintenance therapy was continued every 8 weeks. Most patients had prolonged inflammation (27 (79.4%) with total UC, 35 patients with CD (56.5%) had ileocolitis), resistance to therapy, including biological drugs (19 (55.9%) in patients with UC and 49 (79.0%) in patients with CD). The effectiveness of therapy was evaluated after 3 months (based on clinical response and clinical remission), 6 and 12 months (endoscopic response and endoscopic remission were additionally evaluated).
Results. After 3 months, clinical remission was observed in 62.5% and 36.6%, respectively. After 6 months, these indicators were 66.7% and 61.0%, and after 12 months, 70.8% and 61.0%, respectively. After 6 months, endoscopic remission was observed in 50.0% of UC patients and 26.8% of CD patients. After 12 months, it reached 58.3% and 31.7%, respectively. The analysis showed greater efficacy in bio-naive patients with CD (steroid-free remission after 12 months – 62.5%, endoscopic remission – 37.5%), as well as patients with non-stricturizing non-penetrating CD (58%). In patients with UC, vedolizumab showed the same effectiveness both in bio-naive patients (70.0%) and as a second-line therapy (71.2%). It turned out to be more effective in patients with moderate UC (76.2%) and steroid-dependent UC (77.8%).
Conclusions. Vedolizumab is effective in achieving clinical response and clinical remission, as well as endoscopic response and endoscopic remission in patients with UC and CD. Given the selective mechanism of action of the drug, it can be recommended as a first-line therapy.
Full Text
##article.viewOnOriginalSite##About the authors
M. V. Shapina
Ryzhikh State Scientific Centre of Coloproctology
Email: nanaeva1987@mail.ru
к.м.н., рук. отд. по изучению воспалительных и функциональных заболеваний кишечника
Russian Federation, MoscowB. A. Nanaeva
Ryzhikh State Scientific Centre of Coloproctology
Author for correspondence.
Email: nanaeva1987@mail.ru
ORCID iD: 0000-0003-1697-4670
к.м.н., зав. отд. гастроэнтерологии
Russian Federation, MoscowReferences
- Халиф И.Л., Шапина М.В., Головенко А.О. и др. Течение хронических воспалительных заболеваний кишечника и методы их лечения, применяемые в Российской Федерации (Результаты многоцентрового популяционного одномоментного наблюдательного исследования). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(3):54-62 [Khalif IL, Shapina MV, Golovenko AO, et al. Chronic inflammatory bowel diseases: the course and treatment methods in Russian Federation (Results of multicenter population-based one-stage observational study). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(3):54-62 (In Russ.)]. doi: 10.22416/1382-4376-2018-28-3-54-62
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017;2(60):7-29 [Ivashkin VT, Shelygin YuA, Khalif IL. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of Crohn’s disease. Koloproktologia. 2017;(2):7-29 (In Russ.)].
- Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации российской гастроэнтерологической ассоциации и ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1(59):6-30 [Ivashkin VT, Shelygin YuA, Khalif IL. Clinical guide of Russian association of gastroenterology and Russian association of coloproctology on diagnostics and treatment of ulcerative colitis. Koloproktologia. 2017;1(59):6-30 (In Russ.)].
- Wyant T, Fedyk ER, Abhyankar B. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. J Crohns Colitis. 2016;10(12):1437-44.
- Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-59 (quiz 660).
- Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083
- Lam MC, Bressler B. Vedolizumab for ulcerative colitis and Crohn’s disease: results and implications of GEMINI studies. Immunotherapy. 2014;6(9):963-71. doi: 10.2217/imt.14.66
- Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab Versus Adalimumab for Moderate to Severe Ulcerative Colitis. N Engl J Med. 2019;381(13):1215-26.
- Vickers AD, Ainsworth C, Mody R, et al. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis. PLoS One. 2016 Oct 24;11(10):e0165435. doi: 10.1371/journal.pone.0165435
- Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017 May;45(10):1291-302. doi: 10.1111/apt.14030
- Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048-64.
Supplementary files
